Newsletter · · Ashutosh Agarwal

Oral Wegovy Hits UK Shelves As Payers Squeeze Access - The GLP-1 Complex - Week of July 13, 2026

GLP-1 and obesity-drug newsletter for the week of July 13, 2026. Novo Nordisk's oral Wegovy reaches UK pharmacy shelves while pharmacy-benefit managers cap monthly costs and US employers walk away from coverage, and PepsiCo reframes GLP-1 eating habits as an opportunity.

The GLP-1 Complex

Week of July 13, 2026: Oral Wegovy Hits UK Shelves As Payers Squeeze Access

The story this week wasn't a trial readout or a pipeline surprise. It was plumbing: who pays, at what price, and how the pills actually reach people. A once-a-day Wegovy pill quietly landed on UK pharmacy shelves, a big US pharmacy middleman put a $200 ceiling on the monthly cost of these drugs, and America's employers kept quietly backing away from covering them at all. Meanwhile PepsiCo's CEO went on live TV to explain how he's redesigning snacks for people who now eat like GLP-1 patients. The science is settled enough; the fight now is over money and access.

TL;DR

  • Novo Nordisk's Wegovy pill is now for sale across UK high-street and online pharmacies, the same 15% average weight loss as the shot, in a tablet, but only privately, not yet on the NHS.

  • The affordability squeeze is the real theme: one big pharmacy-benefit manager is capping weight-loss GLP-1s at $200 a month, even as small US employers drop coverage entirely and workers push back.

  • Big Food is adapting, not dying. PepsiCo's CEO says GLP-1 shoppers still buy treats, just in 100-calorie portions, and pointed to a $3.5 billion portion-control business that's growing fast.

What's new

The oral pill is a real product now, not a press release. On The Naked Scientists Podcast (July 10), Cambridge obesity scientist Giles Yeo confirmed that Novo Nordisk's oral version of Wegovy (the pill form of semaglutide) is now on sale at UK high-street and online pharmacies, after launching in the US "at the start of the year." The key line for anyone modeling this market: "people are losing on average 15% of their body weight over two years, either the pill or the injection, they're equally effective." A pill that matches the injection changes the manufacturing math (no cold-chain syringe) and widens who will actually start treatment. The catch is access, it's private-pay only in the UK for now, not covered by the NHS, and Yeo noted that "95% of the people taking these Wegovy jabs, Mounjaro jabs... are doing them privately."

A major pharmacy middleman is trying to cap the price. On Bright Spots in Healthcare (July 7, a rebroadcast this week), Harold Carter, a senior vice president at Express Scripts, one of the country's largest pharmacy-benefit managers, the companies that negotiate drug prices for employers and insurers, described capping the cost of weight-loss GLP-1s at $200 a month for the plans they serve, versus the "$500, $1,000, et cetera" people pay buying direct. The number that should stick with investors is his churn figure: "Over 50% of patients that are on a GLP-1, they're off therapy. They fall off therapy within the first year." That single fact reframes the whole revenue story, these are drugs a lot of people quit, which cuts both ways for volume forecasts and for the "wraparound support" businesses trying to keep people on them.

Employers are quietly walking away from coverage. On The Readout Loud (July 9), STAT journalist Bob Herman laid out his reporting on collapsing job-based insurance. His blunt framing: "Price times quantity equals the premium. And GLP-1s are really just kind of stretching every employer budget imaginable... it's forcing some employers, like, no, we're not even going to cover GLP-1s anymore. And that's creating a completely different form of backlash among workers." He found small businesses (50 or fewer employees) dropping health plans entirely, one Chicago firm of under 10 people simply took a year off insurance; a Pennsylvania clinic chain got hit with a roughly 15-point premium surcharge just for hiring more staff. With enhanced Affordable Care Act subsidies now expired, the pressure on the commercial-coverage base is building, not easing.

PepsiCo is treating GLP-1 as an opportunity, out loud. On Squawk on the Street (July 9), with the stock down about 4.6% on a soft North American quarter, CEO Ramon Laguarta gave the clearest operator read yet on how these drugs change eating: "GLP-1 consumers are basically over-indexing in four things. One is hydration. The other one is fiber, protein. And the GLP-1 consumers stay within our categories, but in small portions. They want to have their treats, but 100 calories, 125 calories, that's the max they're willing to take." His answer is to sell them smaller packs and more protein and fiber, pointing to a portion-control multi-pack business "already almost $3.5 billion and growing at a very fast pace," alongside Gatorade, Propel and Quaker. His verdict: "We see it more as an opportunity than a threat long term." Host Jim Cramer added that Nestle is spending real effort figuring out how to "trick the palate" for these customers.

The liver-disease indication is quietly becoming a big deal. On HeartBEATS from Lifelong Learning (July 8), University of Chicago clinicians walked through the data on GLP-1s for MASH, a serious fatty-liver disease (short for metabolic dysfunction-associated steatohepatitis). Semaglutide got accelerated FDA approval in August 2025 based on the ESSENCE trial (about 800 patients with biopsy-confirmed disease): 62% saw their MASH resolve without their liver scarring getting worse, versus 34% on placebo. They noted the affected population is enormous, the broader fatty-liver condition touches roughly 38% of people worldwide and about 70% of people with type 2 diabetes, so this is a large new use, not a niche one. Tirzepatide showed a similar 62%-versus-10% result in a mid-stage liver trial but is not yet FDA-approved for it.

The debate

The bull case (well-voiced this week): demand keeps finding new doors. A pill that works as well as the shot removes the needle objection (The Naked Scientists). The list of things these drugs treat keeps growing, from fatty-liver disease (HeartBEATS) to type 2 diabetes in newly diagnosed patients, where endocrinologist Javier Morales walked through tirzepatide's edge over standard care on PeerView (July 8). Clinicians on Docs Who Lift (July 7) even described prescribing GLP-1s to lean PCOS patients (BMI 24-25) to restore ovulation, a use insurance doesn't yet recognize, but one that hints at how wide the real-world demand runs.

The bear case (also voiced, and sharper than usual): these drugs are expensive and a lot of people quit them. Express Scripts' own executive put first-year drop-off above 50% (Bright Spots). And on Weight and Healthcare (July 11), patient advocate Ragen Chastain read out the less-flattering side of the trial tables from a paper she co-authored: in the STEP 1 trial, 49.5% of semaglutide patients failed to lose even 15% of their body weight over 68 weeks; in SURMOUNT-1, 63.8% of tirzepatide patients failed to lose 20% over 72 weeks; and in the two-year SELECT analysis, 95.1% failed to lose 20%, with average loss falling to about 10% and nearly 90% of participants gone by four years. The point isn't that the drugs don't work, it's that the biggest-headline results describe a minority of patients, and the affordability crunch (The Readout Loud) collides directly with that reality.

Read-throughs

Packaged food and drink. The clearest read-through of the week: reformulation is real. Beyond PepsiCo's portion-control and protein push, The Best One Yet (July 8) flagged that food giants including Nestle are adding salt and spices to major brands because GLP-1s dull users' taste buds, so keeping products palatable now takes more flavor, not less.

Telehealth and compounding. The compounding-versus-branded fight isn't going away. On On The Pen (July 8), host Dave Knapp dug into a Gallup poll of more than 5,000 patients: 39% on compounded GLP-1s called their treatment "extremely effective" versus 32% on branded, a gap he credibly attributes not to the molecule but to the coaching, nutrition and support that telehealth wraps around it. On Hims's own show, Hims House (July 7), guest Ryan MacDonald sized the broader peptide market at "north of $30" billion over time, about $3 billion immediately addressable in today's gray market, plus larger "health optimizer" and GLP-1-adjunct pools, all hinging on how the FDA reclassifies these compounds. (Worth remembering that's a bullish view aired on Hims's own channel.)

Logistics. A smaller but real one: Supply Chain Now (July 10) highlighted that GLP-1 shots need a tight 36-46°F cold chain all the way to the patient, creating demand for temperature monitoring and theft prevention, one more reason the oral pill's simpler handling matters.

One to file under rumor, not fact. On the enthusiast show GSD Mode (July 12), two peptide users speculated that Eli Lilly is trying to get its next-generation drug retatrutide reclassified as a "biologic", a category that would make it far harder for compounders to copy. It's an intriguing strategic angle if true, but it came from personal-use hobbyists with no sourcing, so treat it as chatter to watch, not a confirmed development.